GLP-1 with Kidney Disease (CKD): The Patient Action Plan

If you have chronic kidney disease (CKD) and your clinician is considering a GLP-1 receptor agonist, the conversation has changed dramatically in the last two years. The FLOW trial (Perkovic 2024, NEJM^[1]) showed that semaglutide 1.0 mg weekly reduced major kidney and cardiovascular events by 24% in patients with type 2 diabetes and CKD (HR 0.76, 95% CI 0.66–0.88). That trial led to the January 2025 FDA approval of Ozempic for reducing risk of serious kidney disease worsening, kidney failure, and cardiovascular death in adults with T2D and CKD^[10] — the first GLP-1 with a kidney-outcomes indication. The earlier AWARD-7 trial (Tuttle 2018, Lancet Diabetes Endocrinol^[2]) had already established that dulaglutide can be used safely down to moderate-to-severe CKD (eGFR 15–59) without dose adjustment. This article is the patient action plan: how CKD is staged, what FLOW and AWARD-7 mean for you, which GLP-1s are dose-adjusted vs not, the lab monitoring you should expect, the ACE-I + ARB + SGLT2 inhibitor interaction map, and the conversation to have with your nephrologist.

The honest summary

• CKD is staged G1–G5 by eGFR (KDIGO 2024 guideline^[6]). G1 = eGFR ≥90 with kidney damage; G2 = 60–89; G3a = 45–59; G3b = 30–44; G4 = 15–29; G5 = <15 or on dialysis. Albuminuria (UACR) is staged A1–A3 in parallel.
• FLOW (Perkovic 2024 NEJM^[1]) randomized 3,533 adults with T2D and CKD (eGFR 50–75 with UACR >300, OR eGFR 25–<50 with UACR >100) to semaglutide 1.0 mg weekly vs placebo. Primary composite (kidney failure, ≥50% eGFR decline, kidney death, or CV death) was reduced 24% (HR 0.76).
• AWARD-7 (Tuttle 2018^[2]) enrolled 577 patients with T2D and moderate-to-severe CKD (eGFR 15–59) and compared dulaglutide 0.75 mg or 1.5 mg weekly vs insulin glargine. Dulaglutide produced equivalent A1c lowering with less eGFR decline at 52 weeks.
• Most GLP-1 receptor agonists require no renal dose adjustment — semaglutide, dulaglutide, liraglutide, tirzepatide. They are largely degraded by peptidases, not renally cleared.
• The load-bearing safety concern is volume depletion and acute kidney injury (AKI) on the background of GLP-1-induced nausea, vomiting, or diarrhea. A patient with G3b–G4 CKD on an ACE-I plus a diuretic plus an SGLT2 inhibitor who then gets 3 days of GLP-1-induced vomiting can develop prerenal AKI in 24–48 hours. Sick-day rules matter.
• Lab monitoring: eGFR and UACR every 3–6 months on a stable GLP-1, more frequently during titration or medication changes.
• Dialysis is not an absolute contraindication. Case series have used liraglutide and semaglutide in hemodialysis patients, but the trial evidence base is thin and this is a nephrologist-led decision.

How CKD is staged: G1 through G5

The 2024 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD^[6] defines CKD as abnormalities of kidney structure or function present for more than 3 months with implications for health. Two dimensions are staged in parallel:

(1) GFR category (G1–G5) based on estimated glomerular filtration rate (eGFR) in mL/min/1.73 m²:

• G1: eGFR ≥90 — normal or high GFR with evidence of kidney damage (albuminuria, abnormal imaging, biopsy findings). G1 without kidney-damage markers is not CKD.
• G2: eGFR 60–89 — mildly decreased, again requires kidney-damage markers for CKD.
• G3a: eGFR 45–59 — mild to moderate decrease. CKD by GFR alone at this point.
• G3b: eGFR 30–44 — moderate to severe decrease. Nephrology referral is typically appropriate.
• G4: eGFR 15–29 — severe decrease. Transplant or dialysis planning conversations begin.
• G5: eGFR <15 — kidney failure (with or without dialysis).

(2) Albuminuria category (A1–A3) based on urine albumin-to-creatinine ratio (UACR) in mg/g:

• A1: UACR <30 mg/g — normal to mildly increased.
• A2: UACR 30–300 mg/g — moderately increased (formerly “microalbuminuria”).
• A3: UACR >300 mg/g — severely increased (formerly “macroalbuminuria”).

The composite stage (e.g., G3aA2, G4A3) drives risk stratification and treatment intensity. KDIGO 2024 explicitly recommends GLP-1 receptor agonist therapy in adults with T2D and CKD who have not achieved individualized glycemic targets despite metformin and an SGLT2 inhibitor, or who cannot tolerate them, with FLOW cited as the primary supporting trial^[6].

Why GLP-1s are increasingly used in CKD: the FLOW trial

FLOW (Perkovic 2024 NEJM^[1]) is the load-bearing kidney-outcomes trial for the GLP-1 class. It randomized 3,533 adults with type 2 diabetes and CKD — specifically defined as eGFR 50 to 75 with UACR >300, OR eGFR 25 to less than 50 with UACR >100 — to once-weekly semaglutide 1.0 mg or placebo, on top of standard care. Median follow-up was 3.4 years.

The primary composite endpoint was a combination of major kidney-disease events (onset of kidney failure, ≥50% eGFR decline from baseline, or kidney death) and cardiovascular death. Semaglutide reduced the composite by 24% (hazard ratio 0.76; 95% CI 0.66–0.88; p=0.0003)^[1]. Individual components moved in the same direction: a 21% reduction in kidney-specific events and a 29% reduction in cardiovascular death.

FLOW also showed a slower annual decline in eGFR slope on semaglutide vs placebo, and the cardiovascular benefit was consistent with the broader GLP-1 CV-outcomes literature (LEADER, Marso 2016^[4]; SELECT, Lincoff 2023^[5]). On the strength of FLOW, the FDA approved Ozempic on January 28, 2025 for reducing the risk of serious kidney disease worsening, kidney failure, and cardiovascular death in adults with T2D and CKD^[10] — the first kidney indication for a GLP-1 receptor agonist.

Important scope notes for patients:

• FLOW enrolled only adults with type 2 diabetes. The kidney-outcomes evidence at this level does not yet extend to non-diabetic CKD.
• The semaglutide dose tested was 1.0 mg weekly (Ozempic dose), not the 2.4 mg weight-management dose (Wegovy). The FDA kidney indication is on the Ozempic label specifically.
• The benefit was on a background of standard care — most participants were on ACE inhibitors or ARBs, and a large fraction were on SGLT2 inhibitors. FLOW is an add-on-benefit trial, not a head-to-head replacement.

AWARD-7: dulaglutide in moderate-to-severe CKD

Before FLOW, the strongest dedicated CKD trial for the GLP-1 class was AWARD-7 (Tuttle 2018, Lancet Diabetes Endocrinol^[2]). It enrolled 577 patients with type 2 diabetes and moderate-to-severe CKD (eGFR 15–59, stages G3a–G4) and randomized them to dulaglutide 0.75 mg weekly, dulaglutide 1.5 mg weekly, or insulin glargine, all for 52 weeks.

Key results: dulaglutide produced A1c lowering equivalent to insulin glargine (about −1.1% to −1.2% at 52 weeks), with less eGFR decline in the dulaglutide arms than in the insulin arm. Patients on dulaglutide also lost about 2–3 kg of body weight across the trial, while the insulin arm gained weight. Safety was acceptable across the full eGFR range tested down to 15. AWARD-7 was the regulatory basis for the dulaglutide label statement that no dose adjustment is needed for CKD G1–G4.

Earlier, the LEADER trial (Marso 2016 NEJM^[4]) randomized 9,340 patients with T2D and high CV risk to liraglutide or placebo. A pre-specified renal substudy (Mann 2017 NEJM^[3]) showed a 22% reduction in new-onset persistent macroalbuminuria with liraglutide. The kidney signal across LEADER, AWARD-7, and FLOW is consistent: GLP-1 receptor agonists slow albuminuria progression and modestly preserve eGFR over years.

Dose adjustments: most GLP-1s don't need one

Unlike many diabetes medications (metformin, most insulins, DPP-4 inhibitors, and SGLT2 inhibitors), GLP-1 receptor agonists are not predominantly cleared by the kidneys. They are large peptides that are degraded by proteolytic enzymes (chiefly DPP-4, neprilysin, and generalized peptidases) in the bloodstream and tissues, with a small fraction excreted unchanged. Practical consequence: renal dose adjustment is generally not required.

Drug-by-drug summary based on FDA labeling and the dedicated CKD trials:

• Semaglutide (Ozempic, Wegovy, Rybelsus): no dose adjustment for CKD G1–G4. Limited data in G5/dialysis (FLOW excluded eGFR <25). FDA kidney indication on Ozempic specifically as of January 2025^[10].
• Dulaglutide (Trulicity): no dose adjustment for CKD G1–G4 based on AWARD-7^[2]. Use with caution in G5; limited dialysis data.
• Liraglutide (Victoza, Saxenda): no dose adjustment for CKD G1–G4; very limited G5 data. LEADER renal substudy^[3] showed albuminuria benefit.
• Tirzepatide (Mounjaro, Zepbound): no dose adjustment for CKD G1–G5 per labeling. Dedicated CKD outcomes trial (SURPASS-CVOT) is ongoing but not yet reported.
• Exenatide twice-daily and once-weekly (Byetta, Bydureon): exenatide is the exception — renally cleared, contraindicated at eGFR <30, dose adjustment recommended at eGFR 30–50.

The clinically important rule: if you are on Ozempic, Wegovy, Trulicity, Victoza, Saxenda, Mounjaro, or Zepbound and your eGFR is 15 or higher, you almost certainly do not need a dose change for kidney reasons. Confirm with your prescriber.

Hydration and acute kidney injury (AKI) risk

The single most important safety topic for GLP-1 use in CKD is volume status. GLP-1 receptor agonists commonly cause nausea, vomiting, diarrhea, and reduced thirst signaling, especially during titration. In a patient with normal kidneys this is uncomfortable but rarely dangerous. In a patient with CKD G3b or worse who is also on an ACE inhibitor or ARB, a diuretic, and an SGLT2 inhibitor, 2–3 days of vomiting can drop intravascular volume enough to precipitate prerenal acute kidney injury — a rapid additional drop in eGFR on top of the chronic baseline.

The Wharton 2022 clinical practice recommendations for managing GI side effects on GLP-1^[9] are the practical baseline:

• Eat slowly, in smaller portions, and stop at the first sense of fullness.
• Stay well hydrated — many GLP-1 patients systematically under-drink because thirst signaling is blunted. A reasonable target on a stable dose is 2.0–2.5 L of fluid per day, individualized by body size and clinician guidance.
• Avoid very high-fat or fried meals, which slow already-slow gastric emptying and amplify nausea.

For CKD patients specifically, layer on the following sick-day rules:

• If you have 24+ hours of vomiting or diarrhea on a GLP-1, contact your prescriber and your nephrologist the same day. Do not wait to see if it improves.
• Many nephrologists advise temporary hold of SGLT2 inhibitors and ACE inhibitors or ARBs during acute gastroenteritis or vomiting illness on the same day-of basis, to protect against prerenal AKI. Pre-arrange these sick-day instructions with your nephrologist.
• Do not under-drink to control nausea. Sip plain water or oral rehydration solution. If you cannot keep fluid down, that is an urgent care visit.

Lab monitoring: eGFR and UACR every 3 to 6 months

KDIGO 2024^[6] recommends monitoring frequency keyed to CKD stage and risk:

• G1A1, G2A1 (low risk): annual eGFR and UACR.
• G3aA1, G3aA2, G2A2 (moderate risk): every 6 months.
• G3bA1 through G4A1, plus G3aA3 and worse (high to very-high risk): every 3–6 months, often with nephrology co-management.
• G4A2/A3, G5 (very-high risk): every 1–3 months, nephrology-led.

When you start a GLP-1 in the setting of CKD, expect your prescriber or nephrologist to check eGFR and UACR 6–12 weeks after initiation, and again at any dose change. An early acute drop in eGFR of up to about 10–15% after starting an SGLT2 inhibitor is well-described and not a reason to stop the medication; the same has not been characterized as cleanly for GLP-1s, but any new sustained drop >15% should be evaluated.

Other labs to discuss with your clinician on this regimen: potassium (especially if on ACE-I/ARB plus mineralocorticoid-receptor antagonist), bicarbonate (metabolic acidosis is common at G4), phosphorus and PTH (CKD–mineral bone disorder), and hemoglobin (anemia of CKD becomes relevant at G3b and below).

The interaction map: ACE-I, ARB, SGLT2, GLP-1 together

Modern CKD management in T2D is rarely single-agent. Patients commonly take a combination of:

• ACE inhibitor or ARB (e.g., lisinopril, losartan) for albuminuria reduction and blood-pressure control — KDIGO Grade 1A in CKD with hypertension and albuminuria.
• SGLT2 inhibitor (empagliflozin, dapagliflozin, canagliflozin) for kidney and CV protection — supported by EMPA-KIDNEY^[7], DAPA-CKD, and CREDENCE.
• GLP-1 receptor agonist for glycemic control, weight loss, and (per FLOW) kidney + CV event reduction.
• Often a mineralocorticoid receptor antagonist (spironolactone or finerenone) in advanced albuminuric CKD.

This combination is now standard of care in T2D + CKD with albuminuria. The combination has additive kidney and CV protection but also additive risks — chiefly hyperkalemia (from ACE-I/ARB plus MRA) and volume depletion/AKI (from SGLT2 plus GLP-1 GI losses plus diuretic).

Practical guidance:

• Do not start more than one of these agents at the same time. Each addition gets its own 4–8 week observation window.
• Check potassium and creatinine 1–2 weeks after starting or up-titrating an ACE-I, ARB, MRA, or finerenone.
• Pre-arrange sick-day rules: if you have acute vomiting, diarrhea, or fever, your nephrologist may want you to hold the SGLT2 inhibitor and ACE-I or ARB for 24–72 hours. The GLP-1 is usually continued, but the GI-loss-amplifying medications come off.
• If you take metformin and your eGFR is between 30 and 45, the metformin dose should be reduced; at eGFR <30, metformin is contraindicated. The GLP-1 does not change this rule.

Dialysis and kidney transplant considerations

For patients on hemodialysis or peritoneal dialysis, the evidence base is thinner than for earlier CKD stages. FLOW excluded eGFR <25 and dialysis patients; AWARD-7 enrolled down to eGFR 15. Published case series and small pharmacokinetic studies have used liraglutide, semaglutide, and dulaglutide in hemodialysis patients without unexpected safety signals, but this evidence base is not at the level of a randomized outcomes trial.

Practical points for dialysis patients considering or continuing a GLP-1:

• Decision should be nephrologist-led, not weight-management-clinic-led.
• Hypoglycemia risk increases on dialysis because of altered drug clearance and reduced insulin clearance; coordinated dose review of insulin or sulfonylurea is essential when adding a GLP-1.
• Anti-emetics and hydration management are even more critical because of the intermittent fluid shifts of dialysis itself.

For kidney transplant recipients, GLP-1 receptor agonists are increasingly being used for post-transplant diabetes and weight management. There is no formal FDA-approved indication for this population, but small observational studies suggest safety. Drug interactions with calcineurin inhibitors (tacrolimus, cyclosporine) are not pharmacokinetic but can be functional via GI absorption changes — coordinated tacrolimus trough monitoring after starting a GLP-1 is reasonable.

How the kidney-event benefit compares to the weight-loss benefit

Insurance and payer pathway for CKD-indicated GLP-1

The January 2025 FDA approval of Ozempic for CKD with T2D^[10] is the cleanest pathway to coverage in this setting. Practical points:

• Medicare Part D plans broadly cover Ozempic for T2D. The FDA kidney indication strengthens the medical-necessity documentation for patients with documented CKD plus T2D.
• Commercial payers typically require documentation of T2D (ICD-10 E11.x) plus CKD stage (ICD-10 N18.x). UACR and eGFR values within the FLOW enrollment range strengthen the prior-authorization packet.
• If your prescriber is targeting Wegovy 2.4 mg (the weight-loss dose) rather than Ozempic 1.0 mg (the FLOW dose), note that the FDA kidney indication is on Ozempic specifically. Wegovy coverage in CKD still routes through obesity criteria.
• See our prior authorization appeal strategy for the line-by-line template if your initial PA is denied.

Patient action plan

1. Confirm your CKD stage and albuminuria category. Ask your primary-care clinician or nephrologist for your most recent eGFR and UACR results. Memorize the composite (e.g., G3aA2). Your treatment intensity follows from these two numbers.
2. Bring FLOW and AWARD-7 into the conversation. If you have T2D plus CKD and you are not yet on a GLP-1, ask your nephrologist or endocrinologist directly: “Does the FLOW trial change my treatment plan?” KDIGO 2024^[6] already recommends GLP-1 therapy in this setting if metformin and an SGLT2 inhibitor have not achieved targets.
3. Verify your current GLP-1 doesn't need a renal dose change. Semaglutide, dulaglutide, liraglutide, and tirzepatide do not require renal dose adjustment for G1–G4. Exenatide does. Most GLP-1 weight-management patients are on the no-adjustment list.
4. Lock in your lab-monitoring schedule. eGFR and UACR every 3–6 months on a stable regimen, plus repeat 6–12 weeks after any dose change or new medication.
5. Pre-arrange sick-day rules. Get written instructions from your nephrologist on which medications to hold for 24–72 hours during vomiting, diarrhea, or fever — typically SGLT2 inhibitor, ACE-I or ARB, and diuretics. The GLP-1 is usually continued unless GI losses are severe.
6. Build the medication list. Use our GLP-1 side-effect timeline to anticipate the titration weeks where nausea is most likely. Plan hydration accordingly.
7. Track UACR trend, not just absolute number. A 50% drop in UACR over a year on combined GLP-1+SGLT2+ACE-I/ARB therapy is the realistic target in albuminuric CKD.

What the evidence does and doesn't say

What it says:

• In T2D with CKD (FLOW enrollment criteria), semaglutide 1.0 mg weekly reduces the composite of kidney failure, eGFR loss, kidney death, and CV death by 24% over a median 3.4 years^[1].
• In T2D with moderate-to-severe CKD (eGFR 15–59), dulaglutide produces equivalent glycemic control with less eGFR decline than insulin glargine at 52 weeks^[2].
• Liraglutide reduces new-onset persistent macroalbuminuria by 22% in high-CV-risk T2D (LEADER renal substudy)^[3].
• Semaglutide reduces major CV events 20% in obesity without diabetes (SELECT)^[5], supporting the cardiovascular component of the dual benefit.

What it doesn't say:

• There is no Phase 3 kidney-outcomes trial of a GLP-1 in non-diabetic CKD. The FLOW indication is T2D-specific.
• The 2.4 mg semaglutide weight-loss dose (Wegovy) was not the dose tested in FLOW. The FDA kidney indication is on Ozempic 1.0 mg specifically.
• There is no randomized outcomes evidence for GLP-1s in dialysis-dependent CKD. Case series only.
• There is no evidence that GLP-1s reverse established kidney damage. The benefit is slowing progression, not reversal.

Bottom line

• CKD plus T2D is now a clear indication for adding a GLP-1 receptor agonist (semaglutide preferred per FDA label^[10], dulaglutide alternative if AWARD-7 fits).
• Most GLP-1s don't require renal dose adjustment down to eGFR 15–30. Exenatide is the exception.
• The combination of ACE-I or ARB, SGLT2 inhibitor, and GLP-1 is the modern standard of care in albuminuric T2D + CKD — with additive benefit and additive AKI risk during acute illness.
• Sick-day rules and structured eGFR/UACR monitoring every 3–6 months are the patient-side load-bearing tasks.
• For non-diabetic CKD, the kidney-outcomes evidence base is not yet there. Weight loss with a GLP-1 in this population is reasonable for obesity reasons but the kidney benefit has not been proven in a Phase 3 trial.

Related research and tools

• FLOW trial deep dive — the full Perkovic 2024 NEJM walkthrough, comparator analysis vs SGLT2 inhibitors, and the path to FDA kidney approval
• GLP-1 for fatty liver and MASH patient guide — the companion patient action plan for the hepatology overlap
• GLP-1 prior authorization appeal strategy — line-by-line template for CKD-indication PAs
• GLP-1 side-effect timeline — week-by-week nausea, vomiting, and diarrhea probability for hydration planning
• Semaglutide drug page — including the Ozempic CKD indication and dosing ladder
• Tirzepatide drug page — renal labeling and SURPASS-CVOT status
• Why am I not losing weight on a GLP-1 (the plateau guide) — CKD patients on lower doses sometimes plateau earlier than the general STEP-1 trajectory

Important disclaimer. This article is educational and does not constitute medical advice. CKD management requires individualized care from your primary clinician and, in most cases, a nephrologist. Do not start, stop, or adjust any medication discussed here without clinician guidance. Sick-day rules for SGLT2 inhibitors, ACE inhibitors, ARBs, and diuretics must be specifically arranged with your nephrology team. Pregnancy and breastfeeding contraindicate most GLP-1 receptor agonists. Patients with a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome should not take GLP-1s. PMIDs were independently verified against the PubMed E-utilities API on 2026-05-28. The FDA Ozempic kidney indication was confirmed against the January 28, 2025 FDA press release.

Last verified: 2026-05-28. Next review: every 12 months, or sooner if a new GLP-1 kidney-outcomes trial reports.